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Abstract
Kufor-Rakeb syndrome is an autosomal
recessive nigro-striatal-pallidal-pyramidal
neurodegeneration. The onset is in the
teenage years with clinical features of Par-
kinson’s disease plus spasticity, supranu-
clear upgaze paresis, and dementia. Brain
scans show atrophy of the globus pallidus
and pyramids and, later, widespread cer-
ebral atrophy. We report linkage in Kufor-
Rakeb syndrome to a 9 cM region of
chromosome 1p36 delineated by the mark-
ers D1S436 and D1S2843, with a maximum
multipoint lod score of 3.6.
(J Med Genet 2001;38:680–682)
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Parkinson’s disease is a relatively common
neurodegenerative disorder aVecting approxi-
mately 1% of the population over the age of 50
years.1 The aetiology is complex and currently
undetermined but involves loss of the
dopaminergic neurones of the nigro-striatal
tract.2 3 Since there is no known curative
therapy, any Mendelian condition that mani-
fests even some symptoms of idiopathic
Parkinson’s disease is of potential interest since
insights into the perturbed neurophysiology
found in such rare conditions may lead to novel
therapies applicable to patients with the
idiopathic form of the disease. We report our
studies of a consanguineous Jordanian family
with four members aVected by Kufor-Rakeb
syndrome, a neurodegenerative disorder in-
volving the nigro-striatal tract, the globus
pallidus, and the pyramids.
The Kufor-Rakeb syndrome was originally
reported by Al-Din et al4 where they described
clinical findings in five aVected oVspring of a
consanguineous couple. These subjects
showed a number of the features seen in
idiopathic Parkinson’s disease including a
mask-like face, rigidity, and bradykinesia but
the onset of the condition was much earlier,
between 11 and 16 years of age, and the disease
was rapidly progressive. Quoting the original
paper: “The features of paralysis agitans were
remarkable in their rate of development
rendering the patients bed-ridden within less
than two years of onset”. Therapy with
levadopa resulted in significant improvement
of extrapyramidal function for up to two years.
Interestingly, intention tremor, a classical
Parkinson’s disease feature, was not seen.
Additional disease features found in Kufor-
Rakeb syndrome that are absent in idiopathic
Parkinson’s disease were spasticity resulting
from corticospinal tract degeneration, a supra-
nuclear upgaze paresis, and the development of
dementia in all aVected subjects. Although the
Kufor-Rakeb syndrome has similarities to
pallido-pyramidal syndrome, it seems to be
distinguished as a separate entity by the
presence of dementia and upgaze paresis seen
in this family together with the lack of intention
tremor.4–7 The oldest aVected subject, who had
a severe spastic paraplegia, was aphasic and
demented, has died following a respiratory
infection. It was not possible to perform a
necropsy. MRI brain scans of aVected family
members showed the progression of disease
with initial atrophy of the globus pallidus and
pyramids, and later generalised brain atrophy.4
The inheritance pattern of Kufor-Rakeb
syndrome was considered to be autosomal
recessive as the parents had none of the symp-
toms seen in their children, they were second
cousins, five of their nine oVspring had the
condition, and, of these, one was female with a
phenotype indistinguishable from that of her
four aVected brothers. We therefore used
autozygosity mapping to find the locus for
Kufor-Rakeb syndrome with samples from the
parents, four of their aVected children, and one
of their unaVected children. The “unaVected”
subject was a 23 year old female; she had no
abnormal neurological symptoms or signs
when examined by the authors and was
considered to have lived through the age of
onset of the condition seen in her aVected sibs.
The CHLC/Weber Human Screening Set
version 8 (Research Genetics Inc) was used in a
genome wide search. This panel contains 365
autosomal microsatellite repeat markers spaced
at approximately 10 cM intervals with an
average heterozygosity of 0.76. PCR amplifica-
tion of all markers was performed according to
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the manufacturer’s specifications using a Ro-
boseq 4200 (MWG BioTech Ltd). Amplified
markers were pooled and electrophoresed on an
ABI Prism 377 gene sequencer (Applied Biosys-
tems) with 4.2% polyacrylamide gels at 3000 V
and 52°C for 2.5 hours. Fragment length analy-
sis was undertaken using the ABI Prism Genes-
can and Genotyper 1.1.1 analysis packages.
The initial genome search identified only
one common region of homozygosity in all four
aVected subjects on chromosome 1p incorpo-
rating markers GATA29A05 and D1S552.
There was no other region where two or more
markers were homozygous or where there was
a potential common haplotype involving three
or more adjacent markers. Fine mapping was
conducted by selecting markers from the ABI
Linkage Mapping Panel Version I (Applied
Biosystems), the Todd Panel,8 and the Marsh-
field Linkage Maps: tel - D1S228 - D1S2672 -
D1S507 - D1S436 - (GATA29A05) -
D1S1592 - D1S2826 - D1S2644 - D1S199 -
(D1S552) - D1S2843 - D1S2828 - cen. This
placed the region on chromosome 1 at band
p36, with meiotic crossovers between markers
D1S228-D1S2672 and D1S552-D1S2843,
with D1S228 and D1S2843 defining the
telomeric and centromeric boundaries. The
results from the unaVected sib further refined
the minimal critical region with a telomeric
crossover between D1S436 and GATA29A05.
Taken together, these results suggest that the
region containing the KuVor-Rakeb syndrome
gene is approximately 9 cM in size with
D1S436 and D1S2843 defining the telomeric
and centromeric boundaries (fig 1). Infor-
mation regarding marker order and relative
distances was obtained from the Marshfield
Linkage Maps. The marker order obtained
from the Marshfield Linkage Maps was in
agreement with that derived from the draft
human genome. An autosomal recessive mode
of inheritance with 95% penetrance was
assumed. The disease allele frequency was esti-
mated at 1 in 150. Allele frequencies for mark-
ers D1S228, D1S436, D1S1592, D1S2826,
D1S2644, D1S199, and D1S2828 were calcu-
lated from the CEPH data for subject 1347-02
(see box 1). Pedigree allele inconsistencies were
Figure 1 Nuclear pedigree (cf Al-Din et al4) of the family with Kufor-Rakeb syndrome
showing microsatellite marker genotypes at chromosome 1p36.Marker order is
tel-D1S228-D1S2672-D1S507-D1S436-GATA29A05-D1S1592-D1S2826-
D1S2644-D1S199-D1S552-D1S2843-D1S2828-cen. The aVected subjects are shown as
shaded. The boxed region indicates the homozygous regions in the aVected subjects. The
dotted box indicates the autozygous segment in the unaVected sib. The minimum
autozygous segment for Kufor-Rakeb syndrome is shown in bold.
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Figure 2 Multipoint linkage analysis of the Kufor-Rakeb family across the autozygous
segment at 1p36 showing lod score results for markers D1S228,D1S436,D1S1592,
D1S2826,D1S2644,D1S199, and D1S2828.
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Box 1
The allele frequencies for some of the mark-
ers we used, D1S228, D1S436, D1S1592,
D1S2826, D1S2644, D1S199, and
D1S2828, have not been published. These
are required to generate lod scores from
linkage analysis programs. Rather than esti-
mate the allele frequencies, we sought a data
source that had used these markers and had
generated human data. CEPH has used
these markers to genotype their CEPH
reference families. By accessing http://
www.cephb.fr/cephdb/dumps the data can
be retrieved. Therefore, we could use the
CEPH data to give us allele frequencies for
markers D1S228, D1S436, D1S1592,
D1S2826, D1S2644, D1S199, and
D1S2828. We had to ensure, however, that
our allele calling/identification was the same
as that of CEPH. To do this we genotyped
one of their reference samples, DNA from
subject 1347-02, against the markers. This
allowed us to ensure that we and CEPH had
identical allele identification. We were then
able to use the CEPH data to produce allele
frequencies for our markers.
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identified using PedCheck.9 Two point analysis
was performed using the LINKAGE analysis
programs10 and multipoint lod scores were
computed by means of the GENEHUNTER
program, version 2.0 beta.11 The two point lod
score at è=0 for markers in the critical region
using CEPH data for allele frequencies were
−∞ for D1S228 and D1S436, +1.14 for
D1S1592, +2.53 for D1S2826, +2.40 for
D1S2644, +2.57 for D1S199, and −∞ for
D1S2828. The highest multipoint lod score
was 3.6 for the chromosome 1p36 region con-
taining markers D1S1592, D1S2826,
D1S2644, and D1S199 (fig 2).
Ubiquitin specific protease 1 (USP1A) has
been mapped cytogenetically to the Kufor-
Rakeb region 1p32-3612 and is a potential can-
didate gene because of the involvement of the
ubiquitin degradation pathway in the auto-
somal recessive Mendelian form of Parkinson’s
disease PARK2.13 However, the gene seems
excluded by radiation hybrid mapping of the
USP1 EST stSG41379 and examination of the
draft human genome browser placing the gene
at 1p22, outside the candidate region for
Kufor-Rakeb syndrome.
The initial features of Kufor-Rakeb syn-
drome are mask-like face, rigidity, and bradyki-
nesia, including a response to dopaminergic
therapies. This strongly suggests that there is a
progressive loss of dopaminergic neurones in
the nigro-striatal pathway, as seen in idiopathic
Parkinson’s disease. The clinical finding of
progressive spasticity and pyramid atrophy on
brain scan show that Kufor-Rakeb syndrome
also involves corticospinal tract degeneration.
One feature of Parkinson’s disease is absent,
tremor. This may be explained by the pallidal
degeneration seen on brain scans of aVected
members of the Kufor-Rakeb family, as pallidal
ablation is used in advanced Parkinson’s
disease to reduce symptoms including
tremor.14 Kufor-Rakeb syndrome is probably,
therefore, a nigro-striatal-pallido-pyramidal
degeneration. We have mapped this disorder to
a 9 cM region of chromosome 1p36. Eventual
identification of the gene causing Kufor-Rakeb
syndrome will lead to a greater understanding
of the complex functions and diseases of the
basal ganglia in man.
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